Source: Sharecast
GSK said Q2 revenues were 5% at £8.1bn, buoyed by its vaccines and specialty medicines divisions, while operating profits climbed 12% to £2.1bn, and adjusted earnings per share rose 7% to 41.8p.
Vaccines led the charge, jumping 15% on the back of demand for its shingles jab, Shingrix, and RSV vaccine, Arexvy. Specialty medicines followed suit, posting a 12% rise, with solid growth in HIV treatments and oncology assets. General medicines, however, slipped 2% due to pricing pressures and competitive headwinds.
Looking ahead, GSK said it was confident of delivering on its FY2525 guidance, noting that turnover growth, core operating profit growth and core EPS growth were all seen towards the top of its guidance range.
Chief executive Emma Walmsley said: "GSK's strong momentum in 2025 continues with another quarter of excellent performance driven mainly by specialty medicines, our largest business, with double-digit sales growth in respiratory, immunology & inflammation, oncology and HIV.
"We now expect to be towards the top end of our financial guidance for 2025 and remain confident in our long-term outlooks."
Reporting by Iain Gilbert at Sharecast.com